{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:37:31Z","timestamp":1776433051510,"version":"3.51.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome, and the proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated myeloid-related proteinemia inflammatory (PAMI) syndrome are two distinct clinical conditions caused by heterozygous mutations of the <jats:italic>PSTPIP1<\/jats:italic> gene. While skin and joint involvements are shared by both conditions, PAMI is characterized by hepatosplenomegaly, pancytopenia, and growth failure. Kidney involvement is exceptional in PSTPIP1-mediated disorders. The two missense <jats:italic>PSTPIP1<\/jats:italic> variants associated with PAMI syndrome are p.E250K and p.E257K. Long-term treatment with interleukin (IL)-1 inhibitors is effective to control inflammatory manifestations and is usually well-tolerated. We report a case of a patient carrying the <jats:italic>PSTPIP1<\/jats:italic> p.E250K mutation who developed a late-onset kidney involvement despite a long treatment with canakinumab and anakinra. Kidney biopsy showed focal segmental glomerulosclerosis that was treated with tacrolimus (0.1 mg\/kg\/day in two doses). A literature revision with the aim to assess the proportion and type of kidney involvement in PAMI syndrome revealed that heterogeneous nephropathies may be part of the clinical spectrum. Our study supports the importance of a periodic diagnostic work-up, including kidney laboratory tests and kidney biopsy, in individuals affected with PAMI syndrome. Kidney and liver functions may be impaired regardless of anti-cytokines treatments and additional therapy approaches (i.e., multi-drugs, hematopoietic stem cell transplantation) should be carefully considered.<\/jats:p>","DOI":"10.3389\/fmed.2021.759092","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:07:50Z","timestamp":1635487670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Kidney Involvement in PSTPIP1 Associated Inflammatory Diseases (PAID): A Case Report and Review of the Literature"],"prefix":"10.3389","volume":"8","author":[{"given":"Paola","family":"Borgia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Ceccherini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Marco","family":"Ghiggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jaci.2015.04.016","article-title":"Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)\u2013associated inflammatory diseases","volume":"136","author":"Holzinger","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/1346-8138.15706","article-title":"Rare cases of PAMI syndrome in both father and son with the same missense mutation in PSTPIP1 gene and literature review","volume":"48","author":"Huang","year":"2021","journal-title":"J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jid.2020.08.028","article-title":"Phenotypic associations of PSTPIP1 sequence variants in PSTPIP1-associated autoinflammatory diseases","volume":"141","author":"Boursier","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.23736\/S0392-0488.20.06629-8","article-title":"PAPA spectrum disorders","volume":"155","author":"Genovese","year":"2020","journal-title":"G Ital Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/BOR.0000000000000314","article-title":"Alarming consequences-autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1","volume":"28","author":"Holzinger","year":"2016","journal-title":"Curr Opin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaci.2020.11.043","article-title":"HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome","volume":"148","author":"Laberko","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/rheumatology\/kew031","article-title":"Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome","volume":"55","author":"Omenetti","year":"2016","journal-title":"Rheumatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semarthrit.2015.02.012","article-title":"Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome","volume":"45","author":"Lindwall","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10875-019-00646-z","article-title":"Autoinflammation masquerading as autoimmunity in an adult with heterozygous p.E250K PSTPIP1 mutation.","volume":"39","author":"Dai","year":"2019","journal-title":"J Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2174\/138920210793175921","article-title":"Clinical, molecular, and genetic characteristics of PAPA syndrome: a review","volume":"11","author":"Smith","year":"2010","journal-title":"Curr Genomics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","article-title":"Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder","volume":"11","author":"Wise","year":"2002","journal-title":"Hum Mol Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"604206","DOI":"10.3389\/fimmu.2020.604206","article-title":"Actin remodeling defects leading to autoinflammation and immune dysregulation","volume":"11","author":"Papa","year":"2021","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/blood-2013-07-516948","article-title":"The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages","volume":"123","author":"Starnes","year":"2014","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum Dis Clin North Am."},{"key":"B15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e20191699","DOI":"10.1084\/jem.20191699","article-title":"Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis","volume":"217","author":"Angeletti","year":"2020","journal-title":"J Exp Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.759092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:07:51Z","timestamp":1635487671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.759092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":16,"alternative-id":["10.3389\/fmed.2021.759092"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.759092","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"759092"}}